US Patent 7105341 In vivo production of cyclic peptides

Patent 7105341 was granted and assigned to Rigel Pharmaceuticals on September, 2006 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 11 Oct, 2023

"update inverses"

Golden AI

edited on 11 Oct, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11780881 Compounds for selective disruption of protein-protein interactions

Edits on 6 Sep, 2023

"Add patent inventor(s)"

Golden AI

edited on 6 Sep, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Inventor Names

Todd M. Kinsella0

Edits on 31 Aug, 2023

"Add patent abstract"

Golden AI

edited on 31 Aug, 2023

Edits made to:

Article (+331 characters)

Article

Patent abstract

The compositions relate to retroviral vectors encoding intein containing polypeptides which, when expressed in an eukaryotic cell, are capable of generating cyclic peptides. The retroviral vectors are used in methods for producing cyclic peptides and for identifying peptides capable of altering cellular phenotypes.

Edits on 22 May, 2023

"Remove website redirecting to Patent Public Search front page"

Golden AI

edited on 22 May, 2023

Edits made to:

Infobox (-1 properties)

Infobox

Official Website

https://pdfpiw.uspto.gov/.piw?Docid=071053410

"Remove leading 0 from patent number"

Golden AI

edited on 22 May, 2023